ICON plc’s Post

Working on the General Pharma Legislation with EuropaBio - the European Association for Bioindustries team was and still is a valuable experience. 🩺 Proposing a revision of the #GPL after 20-year means a chance to strengthen European competitiveness in the development of cutting-edge therapies and medicines. 🏥 It is necessary to translate #EU market ambitions into concrete actions to reinforce the European biotech ecosystem, promoting innovation and ensuring effective and faster access to medicines. 🧬More #biotech innovations in the EU means more quality for EU healthcare systems. 🔗 If you want to read more about this: https://lnkd.in/d5Hs3f_U  

Chicago's climb to 9th place in GEN's Top Biopharma Clusters list underscores our city's growing magnetism for life sciences innovation and company expansion. We're seeing more biotech firms choosing Chicago for their growth, attracted by our world-class research institutions, skilled workforce, and supportive ecosystem. This ranking reflects the hard work of our community and signals to the industry that Chicago is not just a place for startups, but a prime location for established companies to scale and thrive

The biotech funding market is highly competitive, but science that addresses unmet clinical needs and drives progress in key therapeutic areas is still receiving funding. However, the science alone isn’t guaranteed to beat the competition. Read investor insights and best practices to maximise your prospects of securing funding in part one of our two-part biotech funding whitepaper series. https://ow.ly/rQsk50RrQZl

Thrilled to see Chicago climb to 9th place in GEN’s 2024 Top Biopharma Clusters, surpassing Seattle! Key drivers of our rise: - Growth in wet lab developments - Chan Zuckerberg Initiative expansion - Booming AI sector As venture capital markets recover, attracting more investment will be crucial to sustaining this momentum. Stay tuned for the Illinois Biotechnology Innovation Organization (iBIO) economic report for deeper insights into our biopharma growth. #Biopharma #Chicago #Innovation #AI #Investment #GENrankings Read more on iBIO NewsBrief.

Bonum Therapeutics' John Mulligan, Ph.D. drops a gold nugget of wisdom in today's #BusinessOfBiotech for anyone who has to make executive decisions. In other words, that's just about everybody. When prioritizing tasks, you generally have three types. Low complexity/high value — these are rare. High complexity/low value — these are abundant. High complexity/high value — these are the Goldilocks tasks. I don't know about you, but I can get confused by those abundant high-complexity/low-value tasks. They're easy to spot but sneaky about hiding their payout value. I bet discerning the difference saves a ton of time and boosts productivity.

In this upcoming webinar, Cook MyoSite's Adam Hostetler will divulge industry secrets for fostering successful biotech partnerships, detailing the importance of defining mutual goals, data sharing guidelines and more. Register now >>> https://hubs.ly/Q02xfyS80

Navigate the ins and outs of strategic industry partnerships with Adam Hostetler, Director of Business Operations at Cook MyoSite, in this upcoming webinar! Register for free and uncover key strategies and best practices for developing a successful biotech partnership >>> https://hubs.ly/Q02xfyJR0

The overall picture of the Swiss biotech industry is quite positive. The Swiss Biotech Report recently published provides an analysis of the 2023 biotech funding as well as other key ratios and statistics: https://lnkd.in/dGSvh2d With Swiss Biotech Association https://lnkd.in/dAtS7hyU

Not easy to start a new company

In the latest episode of Exceptional Leaders / Exceptional Ideas, our CEO Tim Van Hauwermeiren discusses his entrepreneurial journey, navigating the launch of argenx, and our approach to developing innovative treatments for autoimmune conditions. Watch the full episode below.